Eisai (TSE:4523) has rolled out LEQEMBI IQLIK in the U.S., offering patients with early Alzheimer's a new at-home option for ongoing treatment after completing initial intravenous therapy. This move ...

By reducing staff and access to treatment, the suspension of USAID and other funding threatens the country’s progress in HIV ...

LEO Pharma A/S, a global leader in medical dermatology, is advancing the understanding of skin disease and its impact on ...

Niagen Bioscience, Inc. , the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

Once you select the base and target currencies from the list and enter the desired amount into the provided field, the currency calculator immediately gives you the result. Additionally, you can also ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing.

Investing.com -- Genmab A/S (CSE:GMAB) shares fell more than 3% on Monday after new data from Johnson & Johnson ’s amivantamab suggested the drug could rival Genmab and Merus N.V. ’s petosemtamab in ...